Covariate‐adjusted adaptive randomization in a sarcoma trial with multi‐stage treatments

We present a Bayesian design for a multi‐centre, randomized clinical trial of two chemotherapy regimens for advanced or metastatic unresectable soft tissue sarcoma. After randomization, each patient receives up to four stages of chemotherapy, with the patient's disease evaluated after each stage and categorized on a trinary scale of severity. Therapy is continued to the next stage if the patient's disease is stable, and is discontinued if either tumour response or treatment failure is observed. We assume a probability model that accounts for baseline covariates and the multi‐stage treatment and disease evaluation structure. The design uses covariate‐adjusted adaptive randomization based on a score that combines the patient's probabilities of overall treatment success or failure. The adaptive randomization procedure generalizes the method proposed by Thompson (1933) for two binomial distributions with beta priors. A simulation study of the design in the context of the sarcoma trial is presented. Copyright © 2005 John Wiley & Sons, Ltd.

[1]  W. R. Thompson.  ON THE LIKELIHOOD THAT ONE UNKNOWN PROBABILITY EXCEEDS ANOTHER IN VIEW OF THE EVIDENCE OF TWO SAMPLES , 1933 .

[2]  M. Zelen,et al.  Play the Winner Rule and the Controlled Clinical Trial , 1969 .

[3]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .

[4]  T. Louis,et al.  Sequential allocation in clinical trials comparing two exponential survival curves. , 1977, Biometrics.

[5]  L. J. Wei,et al.  The Randomized Play-the-Winner Rule in Medical Trials , 1978 .

[6]  J. Bather.  Randomized Allocation of Treatments in Sequential Experiments , 1981 .

[7]  D. Rubin,et al.  Statistical Analysis with Missing Data. , 1989 .

[8]  Stephen G. Eick,et al.  The two-armed bandit with delayed responses , 1988 .

[9]  J. Ware.  Investigating Therapies of Potentially Great Benefit: ECMO , 1989 .

[10]  D. Berry,et al.  Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. , 1995, Statistics in medicine.

[11]  William F. Rosenberger,et al.  New directions in adaptive designs , 1996 .

[12]  H. Sung,et al.  Evaluating multiple treatment courses in clinical trials. , 2000, Statistics in medicine.

[13]  Philip W. Lavori,et al.  A design for testing clinical strategies: biased adaptive within‐subject randomization , 2000 .

[14]  R. Benjamin,et al.  Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Lurdes Y. T. Inoue,et al.  Adaptive Decision Making in a Lymphocyte Infusion Trial , 2002, Biometrics.

[17]  H. Sung,et al.  Selecting Therapeutic Strategies Based on Efficacy and Death in Multicourse Clinical Trials , 2002 .

[18]  H. Sung,et al.  Multi-Course Treatment Strategies for Clinical Trials of Rapidly Fatal Diseases , 2002 .

[19]  Roderick J. A. Little,et al.  Statistical Analysis with Missing Data: Little/Statistical Analysis with Missing Data , 2002 .

[20]  S. Murphy,et al.  Optimal dynamic treatment regimes , 2003 .

[21]  Ree Dawson,et al.  Dynamic treatment regimes: practical design considerations , 2004, Clinical trials.

[22]  H. Robbins.  Some aspects of the sequential design of experiments , 1952 .